Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare the Efficacy and Safety of Micafungin Versus Conventional Amphotericin B for the Treatment of Neonatal Candidiasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infant greater than 48 hours of life after birth up to day of life 120 at the time of culture acquisition~* Diagnosis of proven invasive candidiasis within 4 days prior to study start~* Subject's parent or legal guardian agrees not to allow subject to participate in another study with another investigational drug while on treatment.~Exclusion Criteria:~* Infant with any history of a hypersensitivity or severe vasomotor reaction to any echinocandin or systemic amphotericin B product~* Infant who has received more than 48 hours of systemic antifungal therapy prior to the first dose of study drug~* Infant who has a breakthrough systemic fungal infection while receiving amphotericin B product or an echinocandin as prophylaxis~* Infant who has failed prior systemic antifungal therapy for this episode of invasive candidiasis~* Infant who is co-infected with a non-Candida fungal organism~* Infant whose positive yeast cultures are solely from an indwelling bladder catheter (unless obtained at the time the indwelling catheter was placed) or sputum.~* Infant previously enrolled in this study

- Gender: ALL
- Minimum Age: 48 Hours
- Maximum Age: 120 Days
- Healthy Volunteers: f

Study Arms:
- Micafungin (Type: EXPERIMENTAL): Infants received micafungin at a dose of 10 mg/kg per day by intravenous infusion for a minimum of 21 days to a maximum of 28 days for infants without end-organ dissemination or for a maximum of 42 days for infants with end-organ dissemination.
- Amphotericin B deoxycholate (Type: ACTIVE_COMPARATOR): Infants received amphotericin B deoxycholate (CAB) at a dose of 1.0 mg/kg per day by intravenous infusion for a minimum of 21 days to a maximum of 28 days for infants without end-organ dissemination or for a maximum of 42 days for infants with end-organ dissemination.

Based on this trial design, predict the completion outcome and termination type (if applicable).